News

News Subscription

Feb 07. 2019
Basilea announces change in the Management Committee - Adesh Kaul appointed CFO
Read more
Download
Jan 24. 2019
Basilea announces collaboration to study derazantinib and atezolizumab (Tecentriq®) in urothelial cancer
Read more
Download
Jan 09. 2019
Basilea reports positive interim results from registrational phase 2 study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma (iCCA)
Read more
Download
Jan 07. 2019
Basilea reports strong, higher than expected preliminary revenue of CHF 133 million for financial year 2018
Read more
Download
Jan 04. 2019
Basilea presenting at the 37th Annual J. P. Morgan Healthcare Conference - delivering on its strategy
Read more
Download
Dec 10. 2018
Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
Read more
Download
Nov 14. 2018
Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium
Read more
Download
Aug 14. 2018
Basilea reports half-year financial results reflecting strong in-market product sales growth in addition to progress and expansion of the R&D pipeline
Read more
Download
Aug 13. 2018
Basilea reports on first Cresemba® approval in MENA region
Read more
Download
Aug 09. 2018
Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB)
Read more
Download